3 results about "Discontinuation" patented technology

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

The invention discloses a system, an operation method and a prediction processor for predicting a patient to stop prescription treatment. The system includes a memory device storing a training dataset including treatment data and patient data for a group of patients and further including an indication as to whether the patient has stopped treatment of a prescription treatment or procedure, at least one patient prediction model, and patient data and previous treatment data for a patient; and a predictive processor receiving treatment data of the patient from the APD machine, storing the treatment data to a memory device, determining a probability that the patient will stop prescription treatment by applying the patient data of the patient, the treatment data, and previous treatment data to at least one patient predictive model, and causing the probability to be displayed within a user interface on the clinician device.

Provided are methods of treating cancer in a human subject. The method includes selecting a subject in need of treatment of cancer; administering to the subject a therapeutically effective amount of gedatolisib at least once a week for a period of three weeks; discontinuing administration of gedatolisib for a period of one week; and resuming administration of gedatolisib at least once a week following the period of discontinuation. The administration for at least a period of three weeks and discontinued administration for at least a period of one week constitutes a cycle, where the cycle is repeated for at least two cycles.